Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01387555 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib
A Phase 2 study, sponsored by Jennerex Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT01387555 is a Phase 2 study that has completed, run by Jennerex Biotherapeutics. The registered enrollment target is 129 participants.
The verdict
NCT01387555, a Phase 2 study, has completed, sponsored by Jennerex Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.
Interventions
- OTHER Best Supportive Care
- BIOLOGICAL JX-594 recombinant vaccina GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2011-10-08 |
| Est. Completion | 2013-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01387555
The ClinicalTrials.gov registry entry for NCT01387555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jennerex Biotherapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Best Supportive Care is the first listed.
NCT01387555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01387555 about?
NCT01387555 is a clinical study titled "A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib". This study is to determine whether JX-594 (Pexa-Vec) plus best supportive care is more effective in improving survival than best supportive care in patients with advanced Hepatocellular Carcinoma (HCC) who have failed sorafenib.
What is the current status of trial NCT01387555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2011-10-08. Estimated completion is 2013-10-01.
What interventions are being tested in trial NCT01387555?
The interventions under investigation include: Best Supportive Care (OTHER), JX-594 recombinant vaccina GM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT01387555?
This trial is sponsored by Jennerex Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.